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Aileen Grant*, Frank Sullivan and Jon DowellAbstract
Background: Prescribing is a core activity for general practitioners, yet significant variation in the quality of
prescribing has been reported. This suggests there may be room for improvement in the application of the current
best research evidence. There has been substantial investment in technologies and interventions to address this
issue, but effect sizes so far have been small to moderate. This suggests that prescribing is a decision-making
process that is not sufficiently understood. By understanding more about prescribing processes and the
implementation of research evidence, variation may more easily be understood and more effective interventions
proposed.
Methods: An ethnographic study in three Scottish general practices with diverse organizational characteristics.
Practices were ranked by their performance against Audit Scotland prescribing quality indicators, incorporating
established best research evidence. Two practices of high prescribing quality and one practice of low prescribing
quality were recruited. Participant observation, formal and informal interviews, and a review of practice
documentation were employed.
Results: Practices ranked as high prescribing quality consistently made and applied macro and micro prescribing
decisions, whereas the low-ranking practice only made micro prescribing decisions. Macro prescribing decisions
were collective, policy decisions made considering research evidence in light of the average patient, one disease,
condition, or drug. Micro prescribing decisions were made in consultation with the patient considering their views,
preferences, circumstances and other conditions (if necessary).
Although micro prescribing can operate independently, the implementation of evidence-based, quality prescribing
was attributable to an interdependent relationship. Macro prescribing policy enabled prescribing decisions to be
based on scientific evidence and applied consistently where possible. Ultimately, this influenced prescribing
decisions that occur at the micro level in consultation with patients.
Conclusion: General practitioners in the higher prescribing quality practices made two different ‘types’ of
prescribing decision; macro and micro. Macro prescribing informs micro prescribing and without a macro basis to
draw upon the low-ranked practice had no effective mechanism to engage with, reflect on and implement relevant
evidence. Practices that recognize these two levels of decision making about prescribing are more likely to be able
to implement higher quality evidence.
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Table 1 Indicators of prescribing quality
• PPI maintenance doses as % of maintenance and treatment doses
• 2.5 mg bendrofluazide as % of 2.5 mg & 5 mg
• Single diuretics as % of single & combined diuretics
• ACE inhibitors per 1000 adjusted population per quarter
• Low dose aspirin per 1000 adjusted population per quarter
• Statins per 1000 adjusted population per quarter
• Hypnotics & anxiolytics per 1000 adjusted population per quarter
• Established antibiotics as a % of oral antibiotics
• Amoxicillin as a % of amoxicillin and co-amoxiclav
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Prescribing medication is a core activity for general prac-
titioners (GPs), and the four-fold variation identified in
the quality and safety of prescribing suggests there may
be substantial room for improvement [1-5]. The quality
of prescribing is determined by using established pre-
scribing measures and applying these to practice data.
Because the passive dissemination of research evidence
has proven inadequate to improve the quality of pre-
scribing [6,7], there has been substantial investment in a
wide range of technologies and interventions designed
to address this issue [8,9]. The extensive literature on
initiatives to encourage the application of research evi-
dence and change professional practice has shown the
effects of these interventions are small to moderate
[10-13]. When it comes to changing professional prac-
tice there are no ‘magic bullets’ [14], and multiple fac-
tors are involved in GPs decisions to change their
prescribing habits [15]. It is recognized multi-faceted in-
terventions are more likely to improve the quality of
prescribing, yet we still know little about why [1,16].
The problem of changing clinicians prescribing behav-
ior has also been explored by a number of qualitative
studies. These have primarily focused on the influences
on the prescribing of new drugs [1,17-19], the influence
of managerial forms of control [20-22], the influence of
specialists [23], the influence of patients [24-29], and lit-
tle change in prescribing as defence of clinical autonomy
[20,21,30,31]. It is recognized there are multiple sources
of influence on GPs prescribing behavior [1,18,32] but
we do not know how these influences become embedded
into routine practice.
There has been widespread interest in managing
organizational culture within the UK National Health
Service (NHS) to improve quality and safety [33,34],
which focuses on organizations under direct NHS con-
trol such as hospitals [35-37] or primary care trusts
[33,38], rather than general practices that are independ-
ently managed [39]. Previous studies using ethnographic
methods have explored the culture of general practice in
relation to financial incentives [40], knowledge manage-
ment [41], and the new General Medical Services
(nGMS) contract [42-44]. A holistic approach to under-
standing the influences GPs recognize when prescribing
is relatively unexplored and findings from qualitative re-
search are needed to better understand prescribing in
general practice [45].
Prescribing is a complicated decision-making process,
undertaken by both patient and doctor, whose intricacies
and influencing factors are not yet fully understood
[46,47]. By understanding more about influences and the
prescribing process, variation in prescribing and the
implementation of current best research evidence may
be more easily explained. This study aimed to betterunderstand the influences GPs recognize when making
prescribing decisions, and why they do not always apply
established and well recognized research evidence (such
as the evidence within the quality prescribing indicators
used by Audit Scotland).
Methods
We carried out an in-depth ethnographic study of three
different general practices in Scotland to explore how
practitioners make prescribing decisions and the influ-
ences they recognize when making these decisions.
Sampling and recruitment
Audit Scotland indicators of prescribing quality were ap-
plied to a year of PRISMs (Prescribing Information Sys-
tem for Scotland) data (April 2005 to March 2006) to
create a sampling frame [48]. We used all nine Audit
Scotland quality indicators specific to prescribing in an
attempt to give a broad measure of good practice (see
Table 1). These indicators included established and well-
recognized research evidence and were regularly used by
the local health board to identify prescribing quality
(discussed further in macro prescribing section). All
practices in NHS Tayside (n = 72) were ranked by their
performance against all measures. Practices that consist-
ently performed well or poorly on these measures were
identified. High ranking practices were selected as prac-
tices which performed well were likely to demonstrate
good practice and the low ranking practice was likely to
provide valuable insights by contrasting practices,
processes and values. Two practices ranked as high
prescribing quality and one practice ranked as low qual-
ity were recruited. The highest ranked practice was
atypical, but the research team felt this practice could
provide some illuminating findings, so another more
generalizable practice was identified to provide compari-
sons with the low-ranked practice. The low-ranked prac-
tice was aware they were not performing well against
prescribing measures but agreed to take part to receive
comparative feedback. Routinely available data were used
to include practice demographics (list size, urban/rural,
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and improve the generalizability of the findings and
recommendations.
Data generation
Data generation was carried out between January 2007
and April 2008. The primary research method was non-
participant observation, triangulated by interviews and
review of practice documentation.
Observation
AG (social scientist) was present in each practice for
three to six months. Practices were observed in sequence
and observation was undertaken in a range of locations:
GP surgeries with all consenting patients (no patient
groups were excluded); home visits; nurse-led clinics; re-
ception; shadowed district nurses, practice managers and
pharmacists; practice meetings (both clinical and admin-
istrative); practice meetings with Community Health
Partnership (CHP) clinical leads; CHP practice pharma-
cist meetings; and a wide range of informal interactions
such as the coffee room, over lunchtime, and tea breaks.
Field notes were recorded as soon as possible after each
observational period.
Interviews
GPs and practice pharmacists took part in semi-
structured interviews after the observation period. This
allowed the findings from the observational research to
be fed into the interviews and offered ‘key’ respondents
an opportunity to comment. All interviews were facili-
tated by a topic guide, conducted in the practices, lasted
approximately an hour, were audio-recorded, and tran-
scribed verbatim.
Documentary sources
A number of practice documents were obtained during
the period of observation: practice protocols and policy
documents; CHP prescribing reports and communica-
tion memos/letters; prescribing review reports; news and
journal articles; clinical management plans; commu-
nication memos; and slides from practice prescribing
meetings. There were no substantial differences in the
availability or number of documents retrieved in each
practice.
Analysis was ongoing, iterative, and was influenced the
researcher’s observations in the field as the study
progressed. AG and JD met regularly to discuss the
emerging analysis. We initially constructed an in-depth
ethnographic description of each practice, detailing the
practice structure, systems, prescribing processes, com-
munication channels, culture, and values. Field notes
were the primary data source. These were supplemented
by appropriate practice documentation and interviewdata. Practice documentation was scanned and/or synop-
sis written of the relevant points and issues. Data were
imported into Atlas.ti 5.5 coded and organized into pat-
terns and categories. JD carried out double coding on a
sample of data, and discrepancies were discussed. An in-
terpretative and constant comparative approach was
used to explain and understand the similarities and dif-
ferences between the three practices [49]. Memos were
written throughout the analytic process and provided a
detailed account of thought processes and amendments
as new data was added. Relevant helpful conceptual and
theoretical frameworks were drawn from; Gabbay and le
May’s mindlines [41], the notion of identity from Weick’s
organizational sensemaking [50], and Sheaff et al.’s soft
governance [51,52].
This ethnographic study was approved by the Tayside
Committee of Medical Ethics B (06/S1402/99).Results
The findings are from 394 hours of participant observation,
nine semi-structured interviews and a review of 46 practice
documents in three general practices in NHS Tayside,
Scotland. These practices have been pseudonymized as
Rubain, Balla, and the Haun.
Disentangling the relationship between long-term pre-
scribing behaviors, the flux of change from regular
reorganization, and the clamour of daily practice activity
was analytically complex. Despite these tensions, pat-
terns of prescribing behavior were strongly evident in
the data. We found the high-ranking practices made two
different types of prescribing decision; macro and micro,
whereas the low-ranking practice made micro-only deci-
sions. Macro prescribing involved strategic policy deci-
sions whereas micro decisions were made about an
individual patient. This paper presents these prescribing
decisions and explores the differences between the high-
ranked practices and the low-ranked practice. This paper
begins with a table (Table 2) detailing the practice char-
acteristics and a description of the different practice nar-
ratives and values, followed by a detailed analytic
discussion of these prescribing patterns.Practice narratives and values
Each practice had a narrative about their organization,
communication strategies, and their values. These narra-
tives were co-created in Rubain and the Haun and were
dominated by the lead GP in Balla. Their narratives were
an important part of their practice identity, ‘what kind of
practice are we?’ [53]. This identity shaped practice
norms: how the practice was organized, how they com-
municated, worked as a team and interpreted and
implemented guidelines likely to improve prescribing
quality.
Table 2 Practice characteristics
Rubain Balla The haun
No. of GPs 3 f/t & 1 p/t 1 f/t & 1 p/t 2 f/t & 5 p/t
Prescribing quality Rank 4/72 (high) 1/72 (high) 71/72 (low)
List size 6000 2000 8500
% Population in most deprived deprivation category quintile* 0.03 1.93 20.58
Location Market town Rural Urban
Practice pharmacist 2.5 days a week 0.5 day a week 3 days a week
*Data from ISD Scotland: Practice populations by deprivation status as at 30th September 2006.
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Rubain staff were proud of being an organized, efficient,
holistic, and accountable practice that provided a high-
quality service to their patients. They viewed prescribing
as an integral part of their service and included cost effi-
ciencies in their definition of quality prescribing. They
valued teamwork, cohesiveness, shared decision making,
consistency in their prescribing behavior and competi-
tion (e.g., prescribing indicator reports comparing prac-
tices in the CHP). Rubain’s values led them to organize
regular face-to-face meetings, have tight protocols and
systems (e.g., to maintain relationship continuity of care),
employ two practice managers, and utilize their informa-
tion technology (IT) system to implement decisions.
Balla
Balla staff were proud of being organized, efficient, hol-
istic, and providing the best possible service to their
local community. They were pleased they were able to
offer patients an on-the-day appointment. High-quality
prescribing, not including cost efficiencies, was viewed
as integral to providing a high-quality service. Balla val-
ued simplicity, creativity, innovation, and change. Balla’s
values of innovation were instigated and implemented
by the lead GP who regularly invested time thinking
about how the practice’s systems and processes could be
improved. This GP valued effective, simple processes,
and systems that he felt allowed him more time to focus
on quality of care and prescribing.
The Haun
The Haun were proud of their modern, egalitarian prac-
tice, which valued part-time working and relied on IT
communication strategies (email and clinical system).
The high number of part-time staff meant the practice
struggled to provide relationship continuity of care, des-
pite all practitioners viewing this as important. The
Haun collectively said they valued clinical autonomy and
tended to shy away from formal and tight organizational
processes and systems. However, some GPs admitted
they felt the practice should move towards a more
system-based approach and retain their egalitarianism.The findings presented are their collective narrative ra-
ther than ‘confessions’ from those prescribers who chose
to build a closer rapport with the researcher.
Two different prescribing decisions
Macro decisions were collective; strategic prescribing
policy decisions which considered the average patient,
one disease/condition, and were focused on one drug.
Influenced by research evidence (primarily guidelines)
and clinical governance mechanisms (practice pharma-
cist, health board formulary, comparative prescribing in-
dicator report). Thus, macro decisions were based on
population-level data about specific groups and largely
ignored contextual and patient level factors. The high-
ranking practices interpreted this information in light of
their population and values and formulated a prescribing
policy. Macro prescribing required research evidence de-
cisions but also communication mechanisms and inter-
est to convert this policy into practice.
Micro prescribing decisions were made during a con-
sultation considering patient views, preferences, circum-
stances and frequently more than one disease. When
making micro decisions, all GPs relied on internalized
personal formularies and clinical judgement, termed
‘prescribing mindlines’. Neither the high- nor low-
ranking practices engaged with research evidence at this
stage.
These decisions were made in different contexts, with
different influences and different people involved. They
could operate independently, but evidence-based, high-
quality prescribing seemed to require a mechanism for
formulating and transferring the macro into micro and
thereby, into practice. Effectiveness of these decisions
was mitigated by practice organizational structure and
communication processes. This point will be addressed
below.
Micro prescribing
Micro prescribing decisions were made by all clinicians.
Micro prescribing was about trying to apply scientific
evidence to the individual patient considering the pa-
tient’s preferences, values, and circumstances, and in
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found prescribers used ‘mindlines’ to make these deci-
sions and confirmed their use specific to prescribing
[41].
Prescribing mindlines
These were personal formularies developed from and in-
formed by their experience of medication (including pa-
tient’s experiences), specialist advice, discussions with
their practice pharmacist and GP colleagues, and the
practice’s macro prescribing policy (if present). GPs
rarely looked up information about medicines and relied
on these prescribing mindlines. For example:
‘I mean things are definitely habitual, I always
prescribe a particular drug, those I know off the top
of my head, why would you prescribe an alternative
that you didn’t know so much about’. (GP 2 interview,
the Haun)
GPs relied on personal experience and social networks
to update their mindlines. These influences are now
discussed in turn.
Experience of medications
Every GP explained they placed their experience of med-
ications as their most valued and strongest influence
over prescribing. Experience was gained over time,
through medical training, years in practice, and exposure
to a number of different prescribing decisions and their
outcome. By prescribing drugs they knew well, GPs
could make expeditious prescribing decisions. In the ma-
jority of consultations observed, GPs tacitly ‘knew’ what
to prescribe. Differences were observed when the GP
was initiating medication or looking after a patient on
medication they did not know well. In this extract from
field notes, the GP switches the patient from a regular
unfamiliar therapy to another that they more often
prescribed:
‘The patient who has entered the consulting room has
just registered with the practice so there are no notes.
The patient comes into the consulting room and
immediately tries to tell the GP how he has been
feeling, he struggles with this and describes the
circumstances by which these symptoms have
occurred in the past. The GP asks this patient a series
of questions and then asks him if it is ‘vertigo or
dizziness’ and the patient says ‘no’. The patient tells
the GP he is on Stelazine and the GP looks up the
British National Formula (BNF) to see if there are any
side effects. The GP prescribes Prochlorperazine
without referring to any guidelines.’ (Rubain,
fieldnotes, 14.02.2008)All the GPs reported bad patient experiences with spe-
cific prescribed medication that influenced their opinion
of those drugs and thus influenced their future prescrib-
ing behavior. With drugs they knew well and commonly
prescribed, one patient’s bad experience did not immedi-
ately influence their opinion.
Secondary care
All the GPs referred to secondary care as one of the
strongest influences over their prescribing. Secondary
care was defined in this study as ‘care that is pro-
vided by specialists or other healthcare staff working
in the clinic upon referral from a GP’. GPs followed
prescribing advice from specialists. This communication
was primarily by letter or discharge note, frequently
hand written only stating the medication that should
be prescribed.
GPs explained following secondary care recommenda-
tions was often how they gained experience of new med-
ications. They read and learned more about the
medication to adequately look after patients. As they
looked after more patients on the medication they
gained experience:
‘There’s been new drugs that have come on-board
and the way they’re being used is according to the
local specialist and how they prescribe’.
(GP 2 interview, Rubain)
GPs became aware of what specialists were prescribing
for a particular disease and came to follow this trend, as
this extract from observation illustrates:
‘The GP prescribed Metformin for a patient who was
overweight and had polycystic ovaries (PCO). After
the consultation I asked about this. The GP explained
that ‘Metformin has been prescribed for the past few
years by gynaecologists. This patient has been trying
hard to lose weight with little success so her PCO
could be why she is not losing weight, so it is a
good excuse to try it and see how she gets on”.
(Balla, fieldnotes, 20.03.2007)
In Rubain and Balla the influence of specialists was
the strongest reason why they deviated from prescribing
policy.
GPs started to notice trends in secondary care pre-
scribing, and if they felt comfortable and had come to
know the medication they emulated this. Thus, pre-
scribing initiated by specialist recommendation was
an important part of the iterative development of
prescribing mindlines. Hospital-initiated prescribing
practices eventually entered a GP’s own mindline through
familiarity.
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In all practices colleagues were valued and trusted as
important sources of information: sharing knowledge,
experiences and asking advice. Colleagues were from
within the practice, other GPs working locally, and
specialists.
Information sharing was regularly observed in all prac-
tices at prescribing meetings, in the coffee room, and
one-to-one in their consulting rooms. Within each prac-
tice, a number of GPs had areas of special interest and
were asked for advice. GPs also reported discussions
with other GP colleagues at external practice events,
such as continual professional development meetings
(CPD).
The quote below illustrates the influence colleagues
had on prescribing:
‘I guess the other doctors in the practice. I mean if
you are, if I have got a difficult problem I will take it
to my other doctors and take advice about what they
would do. Seeing what colleagues have done when
you look at the notes, somebody is prescribing this or
somebody treats that why, what comes out of
hospital, hospital doctors recommend’.
(GP 1 interview, the Haun)
Regular daily conversations in Rubain and Balla
involved clinicians discussing or sharing work but also
narratives about patients. The GPs in these practices
used the coffee room at lunchtime specifically to be
available for discussions. Rubain also had a morning
meeting where they divided up home visits and
liaised with reception and practice managers. The
organizational features of the Haun meant collective
informal discussion was more difficult, so they tended to
have these conversations one-on-one, with trusted others
behind closed doors.
When apprehensive about a prescribing decision, they
sought advice and/or reassurance from colleagues. On
occasion, these narratives were about letting off steam,
for example:
‘Dr A is expressing his frustration at Dr B about a
problem he is having getting medication for a patient.
The Dr prescribed a medication but the village
pharmacy does not stock it. The GP then contacted
the specialist who suggested something else but the
pharmacy does not stock this either’. (Rubain,
fieldnotes 28.02.08)
The GPs in all practices asked their pharmacist for
advice on individual patients, advice on dosing,
interactions, or suggestions about what to prescribe.
Practice pharmacists searched the relevant literatureand the national formularies (BNF and Martindale’s
Pharmacopoeia). Practice pharmacists were employees of
the local health board and based in practices to improve
prescribing (further information in the macro prescribing
section Page 11):
‘People who are on drug interactions or side effects
from the drugs, she is very good at, if we’ve got
queries about drugs or dosages or interaction she’s
very good at that’. (GP 3 interview, the Haun)
Colleagues have tacit knowledge that can be difficult
to retrieve from other sources. Conversations in
communal spaces ensured these were open to all
prescribers. These interactions resulted in the itera-
tive development and modification of prescribing
mindlines. Through regular communication and
discussions in Rubain and Balla, we hypothesized
prescribers developed shared prescribing mindlines
but retained a degree of individual interpretation based on
their personal experience, preferences, and values. In
the Haun, the large number of part-time staff and
lack of face-to-face communication mitigated the collective
sharing of stories and mindlines, contributing to low
prescribing quality.
Drug representatives
All practices played down their engagement with
drug representatives, though all did occasionally use
them to provide a ‘free’ lunch. Drug representatives
were present in Balla and the Haun approximately
once a month and on a more ad hoc basis in
Rubain. In Balla, the second GP felt she did not
have time to keep up-to-date so would see represen-
tatives. All GPs reported viewing the representatives
with scepticism:
‘They used to be more of an influence in the old days.
They don’t tend to influence things so much these
days because we always tell them that for any change
in our prescribing it would have to be discussed with
(pharmacist named) and so they should speak to
(pharmacist named). You do tend also to find that
they tend to all be promoting the same type of
medicine anyway’. (GP1 interview, Rubain)
As prescribing trends in PRISMs data were difficult
to observe, it was impossible to measure the effect
of a drug representative visit on each practice.
Although information from drug representatives was
likely to have a subtle effect on GP’s prescribing
mindlines, no consultations were observed where the
promoted drug was prescribed subsequent to the
representative visit.
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At the micro level, evidence and information relevant to
prescribing was internalized through applying it to pa-
tients. GPs observed how patients responded to medica-
tion initiated in secondary care. When there was little
alternative, GPs tried a new drug or dose. If the patient
responded well, GPs would try this in another patient
with similar symptoms and risk profile. GPs observed
how patients responded to this medication by engaging
in closer monitoring and follow up. Discussing this with
colleagues was another important mechanism for the in-
ternalization of evidence at the micro level.
Applying prescribing mindlines
Prescribing mindlines were applied to individual patients
considering their preferences, values, and circumstances.
GPs and patients did not engage in shared decision mak-
ing about whether to prescribe or not and rarely in the
choice of preparation. Patients were observed actively
being involved in decisions about the method of admin-
istration, such as capsules instead of tablets. Although
patients were not interviewed, they appeared to be satis-
fied with this level of involvement.
Macro prescribing
These population-based decisions were influenced by
guidelines and clinical governance and were shaped
by practice values, organization, and communication
channels.
Soft governance mechanisms
Health Boards and Community Health Partnerships
(CHPs) are accountable in Scotland through clinical gov-
ernance to ensure prescribing is evidenced based and
cost effective. GPs have independent contractor status,
therefore cannot be managed by traditional command
and control mechanisms. Sheaff et al.’s work illustrated
the fact that CHPs use a range of soft governance mech-
anisms to influence prescribing [52]. These techniques
try to appeal to professional values and build relation-
ship and rapport between the CHPs and practices [51].
By doing so these approaches are dependent on how
practices legitimized them [52]. Each soft governance
mechanism witnessed is discussed in turn below.
Health board prescribing formulary
The health board formulary is a guide of recommended
drugs intended to direct choice towards a rational selec-
tion of drugs based on clinical efficacy, safety, patient ac-
ceptability, and cost-effectiveness. Rubain and Balla
modified this formulary to suit their preferences and ex-
perience by developing their own formulary. Rubain set
reminders on their clinical system to reinforce this. Prac-
tice formularies listed fewer drugs than the health boardformulary. This allowed practices to retain some clinical
autonomy, yet rationalize and standardize their prescrib-
ing. The Haun did not place such value on consistency;
they tended not to discuss what they prescribed and
trusted individual professional opinion:
‘I have to say I think that prescribing policy is
something that perhaps we could be tighter on in this
practice, we don’t really have a formal, this is the drug
that we use for this situation in this practice, we tend
to prescribe what we want to prescribe ourselves as
individuals’. (GP 1, interview, the Haun)
Prescribing indicator report
CHPs produced a prescribing report, which presented
practices ranked by their performance against quality
and cost-efficiency indicators applied to PRISMs data,
with the intention to motivate practices by peer com-
parison. Rubain legitimized these performance indicators
and responded to this sense of competition. At their pre-
scribing meetings, they collectively reviewed their per-
formance and identify areas for audit. They had been a
fundholding practice, and the research team related their
experience at critiquing prescribing to this:
‘We have meetings with (pharmacist named) once
every four weeks, the last Friday of the month. First of
all, we look at, because of our prescribing, a monthly
update in terms of how our prescribing compares
with the CHP average and so on and he recommends
changes to our prescribing patterns’. (GP 1 interview,
Rubain)
Balla and the Haun did not value the prescribing re-
port due to the limitations of PRISMs data. PRISMs
measures cost and volume and is not linked to case-mix.
These practices had older and younger populations, re-
spectively, than the health board and national averages
and felt this skewed their data.
Practice pharmacists
Practice pharmacists were the most sophisticated and
legitimized of the soft governance mechanisms. They
were champions of rational prescribing, building rela-
tionships and rapport, and legitimizing CHP policy
and priorities by appealing to relevant practice values.
They were employees of the health board but based
within practices to facilitate rapport, legitimization
and improve prescribing.
The role of practice pharmacists was very distinct in
comparison to traditional community and hospital phar-
macy positions. They were responsible for disseminating
and implementing CHP prescribing policy (both quality
and cost) and new guidelines; conducting clinical audits;
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part of rapport and relationship building to facilitate im-
plementation of CHP policy. Due to varying degrees of
legitimization of CHP policies, managerial forms of con-
trol and the practice organization the roles and responsi-
bilities of each pharmacist varied:
‘Because our roles have generally evolved rather than
being dictated. They tend to evolve within the
practice depending on what the practice priorities are
and I suppose the interests of the practice pharmacist
and the GPs as well’ (Practice pharmacist interview,
the Haun)
In Rubain, their pharmacist adopted a strategic role
spending most of his time influencing the practice’s pre-
scribing policy. He helped them keep up-to-date with
the evidence, constrain the cost of their prescribing, and
conducted medication reviews. In Balla, their pharmacist
had an operational role where she carried out the prac-
tice’s warfarin clinic, conducted the occasional medica-
tion review, and provided advice on an individual patient
basis. In the Haun, their pharmacist carried out an oper-
ational and strategic role. She was involved in filtering
evidence and CHP policy into the practice, but because
the practice did not have a prescribing policy her effect
was limited to her operational role (audits, medication
reviews, processing and checking secondary care recom-
mendations, and providing advice).
The pharmacist’s strategic role was viewed as a pre-
scribing leadership role by the two larger practices. The
Haun and Rubain relied on their practice pharmacist to
inform them of the latest evidence (usually guidelines).
The pharmacists had a preferred hierarchy of guidelines,
with Scottish Intercollegiate Guidelines Network (SIGN)
guidelines first and foremost, followed by National Insti-
tute for Health and Clinical Excellence (NICE), and local
health board and CHP guidance. GPs felt they did not
have sufficient time to keep up-to-date and to reflect on
new evidence. The pharmacists filtered evidence through
prescribing meetings that also facilitated the dissemin-
ation of CHP policies. In all practices, the GPs trusted
what the pharmacist said and did not question the
sources, but they did challenge some of the CHP cost-
saving initiatives.
Only in Rubain was the pharmacist able to fully en-
dorse CHP policy, due to them valuing cost-efficiencies.
In the Haun and Balla, pharmacists were limited in their
ability to persuade GPs due to organizational con-
straints. In Balla, the pharmacist was only in the practice
one morning a week and spent much of this time run-
ning the practice’s warfarin clinic. Also, the lead GP
liked to keep on top of the evidence himself, limiting op-
portunity for their pharmacist. The pharmacist diddistribute CHP policies, but due to her limited time she
was unable to engage in face-to-face discussion. In the
Haun, the high number of part-time staff and lack of
collective face-to-face communication limited her effect.
Practice pharmacists were seen to have specialist skills
in interpreting guidelines and CHP policies in light of
practice populations. The pharmacists were able to audit
and interpret this information in the clinical system data.
Implementing macro prescribing policy involved identify
the numbers of patients affected, gauging whether they
needed to call them in for a medication review or oppor-
tunistically review and not start any new patients on the
drug and/or dose.
Prescribing meetings
Prescribing meetings in Rubain and the Haun had differ-
ent atmospheres to reflect their different values towards
managerial forms of control and consistency in their
prescribing behavior. In Rubain, these meetings were
generally punctually attended by all clinical staff. The
practice pharmacist presented the information in detail
by PowerPoint presentation, that were actively discussed:
‘First of all … a monthly update in terms of our
prescribing compared with the CHP average and so
on and he recommends changes to our prescribing
patterns. Obviously usually with evidence based in
terms of recommendations from NICE or SIGN
guidelines or whatever, and we discuss it and almost
invariably we agree with what he says’ (GP1 interview,
Rubain)
Whereas in the Haun, these meetings were poorly and
not punctually attended (they were also not regularly
scheduled). The pharmacist’s agenda was on various
pieces of paper (many scrap) and the GPs accepted her
recommendations. The informal nature to these meet-
ings fitted well with the organizational culture of the
practice rather than a lack of interest by the GPs. The
practice was going through a period of turbulence, and
business issues were dominating. Regardless, without a
prescribing policy and formulary there was less need for
discussion, and the practice pharmacist was limited in
her effect. These meetings were used by the GPs as a
means of keeping up-to-date with the evidence.
In Balla, they had more general clinical meetings
where prescribing policy was discussed, unfortunately
due to the pharmacist’s limited time at the practice she
was unable to attend.
Why was macro prescribing not taking place in all
practices?
There were differences in practice identity, characte-
ristics, and organization that influenced adoption and
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ation in their prescribing practices.
Rubain and Balla were systematic and organized. The
Haun was also coming to increasingly value being orga-
nized and was undergoing a culture shift towards tighter
processes and systems during the period of observation
as a result of the New General Medical Services (nGMS)
contract.
Rubain and Balla were proactive, holding meetings to
anticipate change and to plan, devising procedures, and
ensuring resources were in place. For example, Balla
planned extensively for a change of IT system, learning
from other practices but also brainstorming to meet
their needs and circumstances and minimize impact to
their daily work. The Haun was going through a period
of turbulence with business issues dominating formal
meetings. The Haun was a reactive practice; they did not
invest the same amount of resources to planning and or-
ganizing clinical systems and processes. The quote below
illustrates this point;
‘I think it is, you do things the way you do them
because it’s the way you do them and you are used to
doing them that way, and I think sometimes it is hard
to take a step back and look and see what you could
be doing differently, because you just assume that you
are doing things and it is working well, and it is not
until there’s a problem that you think well we should
really have had a system to try and stop that problem
happening, if only we’d been doing this and this, this
would never had happened. But until, I think you
just plod along, you are busy doing other things, you
don’t have a lot of time to sit and think about it’.
(GP 1 interview, the Haun)
The two practices that performed well against the pre-
scribing measures both had leadership; both Rubain and
Balla had clinical and administrative leadership, however
in Balla these roles were performed by the lead GP. The
Haun was an egalitarian practice, with no clinical leader-
ship and the practice manager heavily involved with
managing reception taking her away from managing the
GPs and other organizational aspects of the business.
Leadership was important for practice organization and
managing change. Practices were constantly being forced
to manage change with reviews of policy and practice
from CHP, HB, and Government, and through modifying
behavior and practice to be in line with the latest
evidence-based medicine (EBM). Leadership involved
ensuring these issues were addressed and dealt with. In
Rubain and Balla, a GP would oversee the clinical and
organizational aspects, albeit with paternal and autocratic
leadership styles, respectively. These clinical leaders
ensured issues were addressed, would drive change, andbe involved in co-ordinating the practice organization.
Rubain and the Haun also had practice managers who
were important in leading the organizational aspects.
Rubain had invested heavily by employing two practice
managers and in the Haun, due to the high number
of part-time staff (both clinical and administrative),
the practice manager spent a considerable amount of
her time organizing reception, rotas, and the day-to-day
practice management.
The two higher-ranked practices had strong organizational
cultures and practice identities that valued and reinforced
organization control, with which macro prescribing
policy fits well. The Haun struggled to organize
collective meetings with a large percentage of their
clinical staff working part-time, with business issues
dominating the practice agenda. The Haun did not
have a strong organizational culture or identity;
operating primarily as a reactive practice. In the
Haun, formulating a macro prescribing policy was more
difficult with their patient mix, and trying to ensure
consistency in prescribing was not a high priority at the
time of observation.
Prescribing decisions are context dependent, so each
practice had to interpret the evidence to suit their local
population. Rubain’s population was mixed, Balla’s popu-
lation was elderly, rural, and affluent, and the Haun was
responsible for a young, urban, deprived population. The
practice populations affected each practice’s culture and
organization. In Balla, they looked after patients who
were generally compliant and with little social problems
in comparison to the Haun who cared for a larger num-
ber of patients with psychosocial problems.
Some GPs in Rubain and Balla were happy to let con-
sultations overrun on the basis of addressing concerns
and educating patients would save time in the future.
GPs in the Haun were not as relaxed about their surger-
ies over running. This practice struggled to maintain
high levels of relationship continuity and was in a cen-
tral urban location with no patient car park and only
short stay fee parking nearby.
There were a large number of factors that influenced
practice adoption and implementation of macro pre-
scribing policy. The Haun illustrated prescribing issues
may not be a practice’s top priority and organizing for
efficient, effective, and evidence-based prescribing re-
quired practices to be proactive and plan in prescribing
meetings with all GPs present, where possible. There
were a number of confounding factors that made this
task more difficult, such as a high number of part-time
staff and a deprived population.
Micro and macro prescribing model
We developed a model to illustrate the influences recog-
nized by practitioners in the high-ranking practices, how
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action between macro and micro prescribing.
In the high-ranking practices new evidence was
discussed and practice-prescribing policy (macro pre-
scribing) was modified, if necessary. Rubain valued cost
efficiencies and legitimized CHP soft governance mecha-
nisms, so CHP policy was also filtered into the practice,
along with new evidence by their practice pharmacist.
This model includes ‘other quality improvement (QI)
efforts’ as GPs reported these in informal conversations
with the researcher, however this was only observed
once. GPs reported taking part in research studies at the
local university and reported presentations by specialists
at CPD meetings.
Because macro prescribing policy was missing in the
low-ranking practice, the influences down the right-hand
side of the model were primarily filtered into practices
via their personal mindlines on an ad hoc basis
(Figure 1).
Discussion
This study found the high-ranking practices continu-
ously made and applied both macro and micro prescrib-
ing decisions, whereas the low-ranking practice only
made decisions at a micro level. These findings suggest
macro prescribing is required to inform the implementa-
tion of research evidence at the micro level. This distinc-
tion raises important implications for current quality
improvement strategies and the EBM movement, and
suggests the need to focus on cultural change in some
practices.
The main difference between the high and low-ranking
practices was the formulation of a macro prescribing
policy. Quality improvement strategies are advocating
consistency and standardization at the practice level
based on research evidence, shifting evaluation, andFigure 1 High-ranking practices prescribing model (Rubain and Balla)management decisions away from the individual doctor
[54]. Macro prescribing decision-making needs to be
supported by organizational processes and systems for
consistent implementation. Good teamwork [55-57] and
effective communication channels are a key part of
providing high-quality care [58,59]. Strong mechanisms
and processes for transferring information and developing
shared meanings for action are crucial [60,61].
Most decisions to prescribe drugs involve a combin-
ation of factors [18]. Research evidence and written in-
formation is only one influence [1,32]. Colleagues are
important social influences [1,30], illustrating individual
and organizational learning can take place at the same
time [62] but requires a well-functioning team [56,63].
Experience shapes the way research evidence influences
clinical practice [64,65]. All these factors contribute to
the development of mindlines, which ultimately influ-
ence prescribing decision making [41,66] at the micro
prescribing level.
Engagement with EBM and clinical governance mech-
anisms took place at the macro prescribing level. Prac-
tice identity, organization, and culture can be barriers to
engagement with EBM and quality improvement mecha-
nisms. Practices need to engage with the evidence and
interpret their practice data to make improvements. To
do this they need to be organized with practice processes
and systems in place that support macro prescribing.
Practices need to value macro prescribing and
consistency in behavior across all GPs for this to be
effective.
Practice pharmacists were essential in the larger prac-
tices to filter research, provide prescribing leadership,
and interpret the evidence in light of the practice popu-
lation. This finding is relatively novel because there has
been little research into the influence and effect of phar-
macists working in general practice. Balla practice,.
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This may be due to their small size, their investment in
system refinements, or due to the clinician’s personal en-
gagement with research evidence. Without a pharmacist,
practices need to find another mechanism to filter and
interpret evidence to inform macro prescribing and lead
to a consistent change in (micro) practice.
Our study found another important difference be-
tween the high- and low-ranking practices was their col-
lective use of the coffee room at certain times, such as
lunchtime. Colleagues were an important source of in-
formation [1,67] in all practices however, having these
conversations in shared spaces rather than one-to-one
allowed others to contribute and learn [41]. The low-
ranking practice had a high number of part-time staff
and a lack of face-to-face communication. By organizing
the practice to have all practitioners in the practice on
the same day could facilitate informal and formal col-
lective discussions.
This work builds on and supports the existing body of
literature in the range of influences recognized by GPs
when prescribing [1,15,18-20,22,41,68-70], and explores
these influences in light of more recent health service re-
forms, such as the nGMS contract [71]. This is the first
study we are aware of which holistically explores all in-
fluences recognized by GPs when prescribing and de-
scribes how they have embedded these influences into
routine practice. Current prescribing quality improve-
ment interventions tackle prescribing at the macro pre-
scribing level [11,72-77]. So those practices that are not
organized to integrate macro prescribing are unlikely to
perform well against quantitative measures of prescrib-
ing quality. The ubiquitous use of electronic medical
records in primary care and the advances in data extrac-
tion and linkage offer huge opportunities to measure
and establish variation at the micro prescribing level.
This can be seen in the growing use of informatics inter-
ventions to identify patients at high-risk of an adverse
drug event [78,79].
Many of the interventions to influence prescribing
have been perceived by the medical sociology commu-
nity as threats to GPs clinical autonomy [20,21,30]. In
this study, soft governance mechanisms were welcomed
at the macro prescribing level as a means to deal with
the overwhelming amount of evidence targeted at GPs,
but these findings support the place of clinical autonomy
at the micro level [31].
Patient perspectives and expectations may have been
expected to play a significant role at the micro level, but
they did not emerge as a major influence on the choice
of preparation (e.g., diclofenac or paracetamol). Although
prescribing mindlines were flexible enough to consider
the patient’s preferences, values, and circumstances, the
GPs and patients rarely engaged in shared decisionmaking about choice of medication. GPs and patients
did engage in treatment decisions about choice of ad-
ministration method (such as oral or topical). This find-
ing is consistent with the published literature [80,81].
Strengths and limitations
By using ethnographic methods, this study was able to
explore routine prescribing practices within three gen-
eral practices. The strength of this work was the number
of hours of observation, in carefully sampled multiple
sites, by a researcher who was not a healthcare profes-
sional. This allowed consideration of factors that may be
taken for granted through an interview study or by
someone with a healthcare background. As life in gen-
eral practice is constantly changing this is a snapshot of
prescribing practices in one health board in Scotland. It
is hoped some of these findings will resonate with GPs
and primary care providers in other contexts. Tayside
Health Board has invested in practice pharmacists more
heavily in comparison to many other health boards, thus
some insights may not be directly transferable to other
settings. Due to the small number of practices included,
this study will also not represent the full range of views
and influences that exist. The practices that took part
were ranked by prescribing quality indicators. These in-
dicators do not represent the full range of characteristics
GPs may attribute to high-quality prescribing, being a
good practitioner, or having an effective organizational
prescribing culture.
Implications for policy and practice
Practices are likely to benefit from recognizing both
different types of prescribing decisions we describe.
Practice identity appeared instrumental in shaping
engagement with EBM and clinical governance, and
influenced practice organization and communication
channels. Organization and communication channels
were also key influences on macro prescribing and
quality improvement.
The EBM movement requires a shift from tacit know-
ledge to clinical practice grounded in data [64]. Practice
pharmacists had an important role feeding new evidence
into practices, interpreting this in their prescribing data
and translating in the context of changing evidence. Re-
cent improvements in prescribing in Scotland may be
partly due to pharmacist involvement [82]. Leadership
was key for interpretation and co-ordinated practice
engagement. Practice meetings were invaluable to pre-
scribing sense making, macro prescribing policy, and im-
plementation. Practice pharmacists are not a luxury
enjoyed by all, however; practices may themselves need
the skills to interpret practice data in the light of new
evidence and collectively modify macro prescribing pol-
icy, and this will require time.
Grant et al. Implementation Science 2013, 8:72 Page 12 of 14
http://www.implementationscience.com/content/8/1/72Clinical judgement is an important part of prescribing
behavior at the micro prescribing level. Macro prescrib-
ing and EBM are difficult to apply in the context of pa-
tient co-morbidities and polypharmacy. At the micro
prescribing level, GPs used prescribing mindlines, devel-
oped, reinforced, and shared with colleagues. Practices
should be aware of how macro prescribing influences
their prescribing mindlines and utilize this.
Currently quality improvement focuses on prescribing
at the macro level. Further work and interventions
targeted at the micro prescribing level are required, such
as the Data Driven Quality Improvement in Primary care
(DQIP) project. This is an informatics-based prescribing
quality improvement intervention currently being tested
in a randomized controlled trial that uses macro pre-
scribing policy to influence micro prescribing [78]. DQIP
applies newly developed prescribing safety measures [83]
to practice prescribing data and feeds this back to prac-
tices in a manner that prompts practices to review pa-
tients at risk due to a range of factors such as age and
co-prescribing.
Conclusion
This research has illustrated practices make two differ-
ent kinds of prescribing decisions, and the influences
upon these decisions vary. Although micro prescribing
will operate at the time of clinical decision making dur-
ing consultations, evidence-based, high-quality pres-
cribing seems more likely to occur when there is a
functional macro prescribing policy. Macro prescribing
policy seeks to ensure prescribing decisions are based on
evidence and applied consistently where possible. Macro
prescribing offers a framework from which GPs deviate
when deemed appropriate. Macro prescribing informs
the micro and without it, the low-ranking practice had
no mechanism to reflect on the evidence in light of their
practice population and internalize this information to
inform their prescribing mindlines and thereby practice.
There is a need for practices to recognize these differ-
ent prescribing decisions and influences and their inter-
dependent relationship. Currently, policy makers and the
EBM movement focus on assessing prescribing in aggre-
gated micro level data [84]. With this focus, judgements
are erroneously made about macro prescribing decisions.
Current prescribing quality improvement initiatives that
target macro prescribing pay insufficient attention to the
delivery and implementation of best research evidence
at the micro prescribing level. This may explain the
small effect sizes of prescribing quality improvement
interventions to date. General practices with lower
prescribing quality are likely to benefit from support with
organizational processes to support macro prescribing.
Only then they will be able to refine this and improve
prescribing for individual patients.Abbreviations
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